Elevance Health Q3 2026: Revenue $50.4B, Adj. diluted EPS $6.99; FY guidance raised

Elevance Health reported Q3 2026 revenue of $50.4B, adjusted diluted EPS of $6.99. The company raised FY 2026 guidance for diluted EPS to at least $22.00 and adjusted diluted EPS to at least $29.00, citing improved performance and stronger Carelon results. Operating cash flow guidance was also increased to at least $6.5B.

Original reporting
Published Oct 21, 2026, 10:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Elevance Health Q3 2026: Revenue $50.4B, Adj. diluted EPS $6.99; FY guidance raised — source image
Decision brief

The 30-second read

$ELVBullishHigh
01

Why it matters

The guidance lift suggests improved profitability and cash generation, likely supporting a price rally.

02

Market read

First‑report earnings and guidance update for a large‑cap insurer; actionable for traders.

03

What to watch

Potential headwinds from Medicaid enrollment declines and membership attrition.

Relevance 9/10Novelty 9/10Timing: today

Background

Elevance Health reported Q3 2026 results with modest revenue growth and announced raised FY guidance.

Company-level read

Ticker impact

$ELVBullishHigh confidence
Context

Elevance Health raised FY 2026 adjusted diluted EPS guidance to at least $29.00 and operating cash flow guidance to at least $6.5 billion.

Expected impact

likely upward pressure as investors price in higher earnings and cash flow expectations

Evidence & confidence

Guidance upgrades are material for a large‑cap health insurer and typically trigger buying.

Market effects

Higher guidance may lift peer health‑benefits insurers and related biotech payers.

U.S. health‑insurance sector could see modest gains.

Limited to U.S. markets; no immediate global ripple.

Counterpoint

If guidance is already priced in, the stock could face a short‑term pullback.

Key entities

  • Elevance Health

    U.S. health‑benefits insurer (ticker ELV).

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$CVSMed

11 Medicare Advantage Insurers Sue CMS Over 2027 Star Ratings and Nearly $4 Billion in Payments

Eleven Medicare Advantage insurers, including CVS Health, Elevance Health, and Centene, sued the CMS over 2027 star ratings, claiming nearly $4 billion in potential losses. They argue CMS used unauthorized measures, citing a recent court ruling in Clover Health's favor. Higher ratings affect bonus payments and rebates. CMS is appealing the Clover decision and has not commented on the new lawsuits.

$MCKHighAI 8/10

Healthcare providers & services stocks Q3 results: Benchmarking McKesson

McKesson (MCK) reported Q3 revenue of $111B, up 7.6% YoY, beating estimates. LifeStance Health (LFST) saw 25.3% revenue growth, while Brookdale (BKD) reported a 12.4% decline. Elevance Health (ELV) and The Pennant Group (PNTG) also released Q3 results, with mixed outcomes. Sector revenues beat estimates by 2.2%, and stocks are up 4.4% on average since earnings.

$UNHHighAI 8/10

Positive Medicaid signals, open enrollment trends: Recapping major payers' Q3 results

UnitedHealth Group reported Q3 profit of $4.1B (up from $2.3B YoY) and revenue of $112.7B. CVS Health earned $2.2B (up from a $4B loss YoY) on $108.4B revenue, announcing a split of its pharmacy business. Cigna and Elevance Health each posted $1.4B profit. Centene reduced losses to $71M (from $6.6B YoY) on $50.6B revenue. Humana saw $162M profit (down from $195M) on $41.15B revenue, with positive Medicare enrollment trends.